News Lilly's BTK drug Jaypirca joins first-line options in US Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA for its first frontline indication, but will it be reserved for later-line use?
News New Lilly combo tops tirzepatide for weight loss in diabetes Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.
News Lilly fleshes out triple G data in diabetes and obesity Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.
News Lilly's rival to Novo's new Awiqli insulin gets FDA approval The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik, setting up a market tussle with Novo's recently launched Awiqli.
News Lilly forges $3.35bn alliance with China's InnoCare Eli Lilly continues a busy period of deal-making with a five-project partnership with InnoCare that includes $100m in upfront and near-term payments.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.